Mechanisms of adaptation and resistance to sunitinib encompass not only the tumour vasculature9, 10 but also epithelial tumour cells,11 such as drug‐lysosomal sequestration,12 via transcription factor EB (TFEB)13 and modulation of ABC transporter subfamily B member 1 (ABCB1) activity, thereby promoting drug efflux and autophagy inhibition.14 Here, ABCB1 is linked to neoplasm.